Efficacy of lamivudine in patients with hepatitis B virus precore mutant infection before and after liver transplantation

American Journal of Gastroenterology

Volumn 94, Issue 3, 1999, Pages 663-667

  Ben Ari, Ziv ^a   Zemel, Romy ^b   Kazetsker, Anna ^b   Fraser, Gerald ^b   Tur Kaspa, Ran ^b  

^a RABIN MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOSPORIN; LAMIVUDINE;

AMINO ACID SEQUENCE; ARTICLE; CLINICAL ARTICLE; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOPROPHYLAXIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; VIRUS MUTATION; VIRUS REPLICATION; VIRUS RESISTANCE;

ANTIVIRAL AGENTS; DNA, VIRAL; DRUG EVALUATION; HEPATITIS B; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HUMANS; LAMIVUDINE; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; POINT MUTATION; RECURRENCE; VIRUS REPLICATION;

EID: 0032979564     PISSN: 00029270     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9270(98)00814-4     Document Type: Article

References (21)

1. Carman WF, Thomas HC. Genetic variations in hepatitis B virus. Gastroenterology 1992;102:711-9.
2. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV DNA and anti-HBe. Gastroenterology 1986;90:1268-73.
3. Hadziyannis SJ, Lieberman HM, Karvountzis MG, et al. Analysis of liver disease nuclear HBcAg, viral replication and hepatitis B virus in liver and serum of HBeAg vs. anti-HBe positive chronic B virus infection. Hepatology 1983;3:652-62.
4. Tur-Kaspa R, Klein A, Aharonson SH. Heptatitis B virus precore mutants are identical in carriers from various ethnic origins and are associated with a range of liver disease severity. Hepatology 1992;16:1338-42.
5. Fattovich G, Brollo L, Alberti A, et al. Long-term follow-up of anti-HBe - positive chronic active hepatitis B. Hepatology 1988;8:1651-4.
6. Brunetto MR, Oliveri F, Rocca G, et al. Natural course and response to interferon of chronic hepatitis B accompanied by antibody to hepatitis Be antigen. Hepatology 1989;10:198-202.
7. Naoumov NV, Shneidner R, Grotzinger T, et al. Precore mutant hepatitis B virus infection and liver disease. Gastroenterology 1992;102:538-43.
8. Samuel D, Muller R, Alexander G, et al. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993;329:1842-7.
9. Konig V, Hopf U, Neuhaus P, et al. Long-term follow-up of hepatitis B virus-infected recipients after orthotopic liver transplantation. Transplantation 1994;58:553-9.
10. Samuel D, Bismuth A, Mathieu D, et al. Passive immunoprophylaxis after liver transplantation in HBs Ag positive patients. Lancet 1991;337:813-5.
11. Davies SE, Portman BC, O'Grady JG, et al. Hepatic histologic findings after transplantation for chronic hepatitis B virus infection, including a unique pattern of fibrosing cholestatic hepatitis. Hepatology 1991;13:150-7.
12. Angus PW, Locarnini S, McCaughan GW, et al. Hepatitis B virus precore mutant infection is associated with severe recurrent disease after liver transplantation. Hepatology 1995;21: 14-8.
13. Fang JWS, Tung FYT, Davis GL, et al. Fibrosing cholestatic hepatitis in a transplant recipient with hepatitis B virus precore mutant. Gastroenterology 1993;105:901-4.
14. Dienstag JL, Perrillo RP, Schiff ER, et al. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 1995;333:1657-61.
15. Grellier L, Mutimer D, Ahmed M, et al. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996;348:1212-5.
16. Bain VG, Kneteman NM, Ma MM, et al. Efficacy of lamivudine in chronic hepatitis B patients with active viral replication and decompensated cirrhosis undergoing liver transplantation. Transplantation 1996;62:1456-62.
17. Ben-Ari Z, Shmueli D, Mor E, et al. Beneficial effect of lamivudine in recurrent hepatitis B after liver transplantation. Transplantation 1997;63:393-6.
18. Okamoto H, Tsuda F, Akahane Y, et al. Hepatitis B virus with mutation in the core promotor for an e antigen-negative phenotype in carrier with antibody to e antigen. J Virol 1994;68: 8102-10.
19. Laskus T, Rakela J, Tong NJ, et al. Naturally occurring hepatitis B virus mutants with deletions in the core promotor region. J Hepatol 1994;20:837.
20. Ling R, Mutimer D, Ahmed M, et al. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 1996;24:711-3.
21. Bartholomew MM, Jansen RW, Jeffers LJ, et al. Hepatitis B virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation. Lancet 1997;349:20-2.